Mitochondria-Targeting Peptoids - Bioconjugate Chemistry (ACS

Subscriber access provided by UNIVERSITY OF TOLEDO LIBRARIES

Mitochondria-targeting peptoids Ho Yeon Nam, Jong-Ah Hong, Jieun Choi, Seungheon Shin, Steve K Cho, Jiwon Seo, and Jiyoun Lee Bioconjugate Chem., Just Accepted Manuscript • DOI: 10.1021/acs.bioconjchem.8b00148 • Publication Date (Web): 26 Mar 2018 Downloaded from http://pubs.acs.org on March 27, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Bioconjugate Chemistry

Mitochondria-targeting peptoids

Ho Yeon Nam,†, ‡ Jong-Ah Hong,§,‡ Jieun Choi,† Seungheon Shin,± Steve K. Cho,+,± Jiwon Seo,†,* and Jiyoun Lee §,*

†

Department of Chemistry, School of Physics and Chemistry, ±School of Life Sciences, Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Buk-gu, Gwangju 61005, Republic of Korea § Department of Global Medical Science, Sungshin University, Kangbuk-gu, Seoul 01133, Republic of Korea +

‡

These authors contributed equally to this work.

*Corresponding authors: Jiyoun Lee, Ph.D. Email: [email protected] Jiwon Seo, Ph.D. Email: [email protected]

Keywords. mitochondria; amphipathic peptoid; mitochondrial delivery; cell-penetrating peptoid

ACS Paragon Plus Environment

Bioconjugate Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ABSTRACT Mitochondria-specific delivery methods offer a valuable tool for studying mitochondriarelated diseases and provide breakthroughs in therapeutic development. Although several small-molecule and peptide-based transporters have been developed, peptoids, proteolysisresistant peptidomimetics, are a promising alternative to current approaches. We designed a series of amphipathic peptoids and evaluated their cellular uptake and mitochondrial localization. Two peptoids with cyclohexyl residues demonstrated highly efficient cell penetration and mitochondrial localization without significant adverse effects on the cells and mitochondria. These mitochondria-targeting peptoids could facilitate the selective and robust targeted delivery of bioactive compounds, such as drugs, antioxidants, and photosensitizers, with minimal off-target effects.


Page 2 of 26

Page 3 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


INTRODUCTION Mitochondria are crucial in cellular physiology, regulating ATP production, calcium homeostasis, and signal transduction. Mitochondria are probably the most studied subcellular organelle, due to their multifaceted functions associated with various diseases,1 such as cancer,2-4

diabetes,5

and

neurodegenerative

diseases.6

However,

interrogation

of

mitochondria-specific proteins and pathways is a challenging task, due to the presence of the two membrane layers that are maintained by an electrochemical potential, which surround a matrix that encloses the mitochondrial DNA. The study of mitochondria depends mainly on subcellular fractionation and fluorescent labeling, using fluorescent proteins and mitochondria-staining dyes. While these methods can specifically isolate or label mitochondria in vitro, given the importance of mitochondria as a disease marker, targeted delivery methods are more desirable for practical applications. Lipophilic carbocations such as triphenylphosphonium (TPP, Figure S1, Supporting Information) ions have been widely used for mitochondria-specific delivery of small molecules.7 Because of the large mitochondrial membrane potential, TPP rapidly accumulates inside the mitochondria and successfully delivers various small-molecule drugs and nanoparticles in vitro and in vivo.8,

9

Cationic peptides such as Szeto–Schiller (SS)

peptide antioxidants10-12 and mitochondria-penetrating peptides (MPPs)13, 14 have also been demonstrated to be useful for mitochondrial transport of anticancer agents and antioxidants (Figure S1). Notably, Kelley and coworkers have developed cationic amphipathic peptides consisting of unnatural amino acids, cyclohexylalanine, and D-arginine.14-16 These MPPs have proven to be useful in studies of mitochondrial pathways and drug-resistance mechanisms because of their synthetic versatility and biocompatibility. However, these cationic peptides are prone to proteolytic degradation, which limits their potential applications for in vivo delivery.



Page 4 of 26

Peptoids are proteolysis-resistant peptidomimetics containing poly-N-substituted glycines. Peptoids have similar physicochemical properties compared to peptides and can be readily synthesized by solid-phase synthesis techniques.17 Polyarginine and polylysine analogs of peptoids

18-20

and peptide-peptoid hybrids

21, 22

have been developed as an

alternative approach to cell-penetrating peptides (CPPs). Several recent studies also found that amphipathic peptoids containing hydrophobic and cationic residues are highly membrane permeable without causing severe toxicity.23, 24 Based on these findings, we speculated that amphipathic peptoids could function as mitochondrial transporters, and set out to design potential candidates. In this work, we evaluated cellular uptake and mitochondrial localization of our peptoid transporters, and analyzed their conformation. In addition, we examined effects of the synthesized peptoids on mitochondrial metabolism and membrane potential as well as cytotoxicity to validate their potential utility as a delivery vehicle.

RESULTS AND DISCUSSION Design and synthesis of mitochondria-targeting peptoids. To construct the cationic amphipathic peptoids, we incorporated one lipophilic residue (marked in bold, Table 1) per two cationic residues, Nlys and Nbtg, to generate a group of three monomers, defined as one repeating unit (n = 1). Overall, we designed peptoids to have 12 monomeric residues (n = 4), which is the optimal chain length for efficient cell penetration.23, 25 We anticipated that this alternating sequence of the lipophilic and cationic residues would resemble previously identified amphipathic transporters, and potentially serve as a platform to control the molecular secondary structure by placing chiral monomers.26,

27

Given that many of the

mitochondria-targeting sequences (MTS) naturally found in mitochondrial proteins have amphipathic helical structures,28 we hypothesized that the added helicity may promote mitochondrial penetration. To investigate cellular uptake and mitochondria-specific


Page 5 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


penetration, we conjugated a carboxyfluorescein (CF) at the N-terminus of each peptoid (1–5) and included three CF-labeled octaarginine and octalysine derivatives (6–8) for comparison. In addition, we synthesized two shorter chain analogs of compound 2 (9–10) to examine the length-dependency of cellular uptake and localization. To assess the mitochondrial toxicity and cell viability, we synthesized the peptoids without CF (11–15). Table 1. Mitochondria-targeting peptoidsa Compounds

Sequence

1

CF-(Nlys-Nch-Nbtg)4-NH2

HPLC elution (%ACN) 38.97

2

CF-(Nlys-Nsch-Nbtg)4-NH2

40.00

7

3

CF-(Nlys-Npm-Nbtg)4-NH2

35.09

7

4

CF-(Nlys-Nspe-Nbtg)4-NH2

35.71

7

5

CF-(Nlys-Ndp-Nbtg)4-NH2

43.13

7

6

CF-(Arg)8-NH2

30.88

7

7

CF-(Nbtg)8-NH2

29.20

7

8

CF-(Nlys)8-NH2

26.32

7

9


38.54

5

10


38.76

3

11

H-(Nlys-Nch-Nbtg)4-NH2

36.47

9

12

H-(Nlys-Nsch-Nbtg)4-NH2

37.75

9

13

H-(Nlys-Npm-Nbtg)4-NH2

30.97

9

14

H-(Nlys-Nspe-Nbtg)4-NH2

32.31

9

15

H-(Nlys-Ndp-Nbtg)4-NH2

41.79

9

a)

Net charge 7

Nch (N-(1-cyclohexylmethyl)glycine); Nsch ((S)-N-(1-cyclohexylethyl)glycine; Npm (N-(1phenylmethyl)glycine; Nspe ((S)-N-(1-phenylethyl)glycine; Ndp (N-(2,2diphenylethyl)glycine); Nlys (N-(4-aminobutyl)glycine); Nbtg (N-(4-butylguanidine)glycine)



As shown in Table 1, ten CF-labeled (1–10) and five unlabeled (11–15) compounds were synthesized. Both peptoid and peptide sequences were synthesized manually according to the solid-phase submonomer protocol17 and standard Fmoc/tBu method,29 respectively (Scheme 1). CF was conjugated at the N-terminus of the sequences by activating the carboxylic acid of 5(6)-carboxyfluorescein with DIC/HOBt. The phenolic hydroxyl group of fluorescein can be acylated during the conjugation reaction and forms phenolic ester side products. Therefore, piperidine was treated to remove the ester-bound CF.30 After the removal of the Mmt protecting group, 1H-pyrazole-1-carboxamidine was added for guanidylation of the primary amines. For unlabeled peptoids, the N-terminal secondary amine was protected using a Boc group followed by Mmt deprotection and guanidylation. Initially, Fmoc protection was attempted using Fmoc-Cl or Fmoc-OSu, but Boc protection always showed superior conversion compared to Fmoc protection. After deprotection and resin cleavage, the purity of peptoids was determined by analytical high performance liquid chromatography (HPLC; >98%) and characterized by electrospray ionization mass spectrometry (ESI-MS; Supporting Information).

Scheme 1. Representative synthetic scheme of the mitochondria-targeting peptoids

Cellular uptake and mitochondrial localization. To evaluate the cellular uptake of the synthesized compounds, we first determined the mean fluorescence intensity of HeLa cells treated with the CF-labeled compounds by flow cytometry (Figure 1). All the newly designed compounds (1–5) showed approximately 10- to 100-fold greater cellular uptake


Page 6 of 26

Page 7 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


than fluorescein alone, indicating that the attachment of the peptoids promoted cellular penetration. In particular, compound 5, which contains biphenyl residues, showed the greatest cellular uptake, exceeding that of the octaarginine peptide (6), probably because of its high lipophilicity. Compounds 1, 2, and 4 also demonstrated slightly better cellular uptake than the polycationic peptoid controls (7 and 8), suggesting that amphipathicity plays an important role in cell penetration.23

Figure 1. Mean fluorescence intensity of HeLa cells treated with compounds 1–8 at 5 µM for 1 h. a Data were compared with the CF-treated control by using a one-way analysis of variance (ANOVA) with Dunnett’s t-test (*: p < 0.05, **: p 100

µM), while compound 15 appeared to be cytotoxic with an LC50 value of 15.6 µM.

Table 2. Percentages of the mitochondrial membrane potential (∆Ψm) and cytotoxicity Peptoid

∆Ψm (%)a

LC50 (µM)b

11

87

>100

12

84

>100

13

112

>100

14

103

>100

15

45

15.6

a

The values are reported as the average values of a duplicate; performed by treating MRC-5 cells with each compound for 72 h.

b

The MTS assay was

Finally, we decided to examine the effects of compound 12 on mitochondrial function, because it showed most selective mitochondrial localization with high cellular uptake. We measured the mitochondrial oxygen consumption rate (OCR) of the cells treated with 12 at



various concentrations by performing the mitochondrial stress tests. As shown in Figure 5, the cells treated with 12 at 10 µM (blue line) maintained normal basal respiration, ATP production, and maximal respiration compared to the untreated control (red line), indicating that the specific mitochondrial localization of 12 did not adversely affect mitochondrial function. Compound 12 appeared to reduce the maximal cellular respiration only at much higher concentrations (50 and 100 µM). Taken together, compounds 11 and 12, which avidly localize to mitochondria, exhibited relatively low mitochondrial toxicity and cytotoxicity, indicating that these compounds can serve as mitochondria-targeted transporters without affecting mitochondrial function.

Figure 5. Effects of compound 12 on the mitochondrial oxygen consumption rate (OCR). U87 cells seeded in an XF24 cell plate 1 day prior to the measurements were equilibrated for 1 h in the presence of varying doses of 12 dissolved in assay buffer. OCR measurements were made during baseline and after injection of oligomycin (2 µM), FCCP (0.5 µM), and rotenone/antimycin A (0.5 µM) in that order. Data are shown as mean ± SEM, n = 4.

CONCLUSION In summary, we identified amphipathic peptoids that are membrane-permeable and specifically accumulate in the mitochondria. In particular, two peptoids with cyclohexyl side chains, 1 and 2, demonstrated highly efficient mitochondrial localization with r-values of 0.69 and 0.81, respectively. These amphipathic peptoids did not significantly affect


Page 12 of 26

Page 13 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


mitochondrial function and were not cytotoxic at low µM concentrations. Although additional structural-activity relationship studies are needed to confirm the mechanism of mitochondrial penetration employed by these peptoids, it appears that the ordered conformation of the amphipathic chain may promote efficient transport, as compound 2 demonstrated the most selective mitochondrial localization. We think that the main advantage of our peptoid transporter is the highly efficient and rapid mitochondrial localization with minimal adverse effects, thus providing a promising alternative to currently studied delivery vehicles. For example, the most widely used mitochondrial targeting cation TPP conjugates produce severe cytotoxicity and disrupt mitochondrial function depending on their physicochemical features, such as valency and polarity,36-38 while most effective MPPs demonstrate moderate cytotoxicity (LC50 ≈ 20 µM).13 Considering the enormous potential of mitochondria-targeting therapeutics, minimizing any possible toxicity issues is crucial. We believe that our mitochondria-targeting peptoids provide a highly selective and robust delivery method that can facilitate therapeutic development.

EXPERIMENTAL General methods. Solvents and reagents were purchased from commercial vendors and used without further purification. Rink amide MBHA resin and Fmoc-Arg(pbf)-OH were purchased from Novabiochem (San Diego, CA, USA). HATU was purchased from ChemImpex (Wood Dale, IL, USA). DIC, DIEA, and TIS were purchased from TCI (ChuoKu, Japan). TFA, DMF, and acetonitrile were purchased from Acros Organics (Franklin Lakes, NJ, USA). Nch, Nsch, and Ndp were purchased from Alfa Aesar (Ward Hill, MA, USA). NMP was purchased from Merck Millipore (Damstadt, Germany). All other reagents for the synthesis of peptides and peptoids were purchased from Sigma-Aldrich (St. Louis, MO, USA). For manual solid-phase peptide and peptoid synthesis, the SPE cartridges



(Applied Separations, Allentown, PA, USA) assembled with the 20 µm filters (Applied Separations) were used for reaction vessels. The reaction was accelerated using a CEM MARS 230/60 microwave reaction system (CEM Corp., Matthews, NC, USA) consisting of a fiber-optic temperature probe and magnetic stirrer under atmospheric pressure. Analytical HPLC chromatograms were obtained using a Waters reversed-phase HPLC system (2489 UV/visible detector, 1525 Binary HPLC pump, 2707 Autosampler, and 5CH column oven) with a C18 column (SunFire C18, 4.6 × 250 mm, 5 µm). The column oven temperature was set at 40 °C. A binary mobile phase system (A: deionized water + 0.1% TFA, B: CH3CN + 0.1% TFA) was used as follows: 2 min 5% of B, linear gradient to 100% of B for 30 min, with 100% B maintained for 5 min. The flow rate was 1 mL/min. The purity of the compound was monitored by measuring the absorbance at 220 nm and 254 nm. All the peptoids were purified on a Waters preparative HPLC system (2489 UV/visible detector, 2545 Quaternary HPLC pump, fraction collector III), with a C18 column (SunFire C18, 19 x 150 mm, 5 µm) at room temperature. The flow rate was set to 14 mL/min. A binary mobile phase system (A: deionized water + 0.1% TFA, B: CH3CN + 0.1% TFA) was employed using 5 min 5% of B, linear gradient to 100% B for 30 min, and 100% B maintained for 5 min. Sample elution was monitored by measuring the absorbance at 220 nm and 254 nm. The purity of each fraction (>98%) was confirmed by analytical HPLC. ESI-MS analysis was performed using a model 1260 Infinity liquid chromatography system (Agilent, Santa Clara, CA, USA) with an Agilent 6120 single quadrupole mass spectrometer. Fractions containing the pure product were collected, lyophilized, and stored at −80 °C. High-resolution mass spectrometry (HR-MS) data were obtained using an Agilent Q-TOF 6520 with dual ESI source. Circular dichroism (CD) spectra were recorded on a model 810 spectropolarimeter (Jasco, Easton, MD, USA) in quartz cells with 10 mm path length. The response time was set to 2 s with 1.0 nm bandwidth for all spectra. For conformational examination, samples were prepared in acetonitrile and


Page 14 of 26

Page 15 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


water. The spectra were acquired in the range of 190–260 nm with a 20 nm/min scanning speed at 20 °C. Spectra recorded three times were averaged. The spectra are expressed in terms of per-residue molar ellipticity (deg·cm2/dmol) based on the chain length of the peptoids. Peptoid concentrations (50 µM) were determined using the dry weight of the lyophilized material, and are based on the TFA salt. General procedure of peptoid synthesis: The microwave-assisted solid-phase submonomer protocol was used for synthesis of peptoids.17, 39Fmoc-Rink amide MBHA resin (0.65 mmol/g, 769 mg, 0.50 mmol) was swelled in DMF (10.0 mL) for 20 min and treated with 20% piperidine in DMF (10.0 mL) at 80 °C in the microwave reactor (600 W max power, ramp 2 min, hold 2 min, stirring level 2). The Fmoc deprotection reaction was repeated twice. The resin was thoroughly washed with DMF (1×), CH2Cl2 (3×), DMF (2×), MeOH (2×), DMF (3×), and CH2Cl2 (3×). Bromoacylation was performed by the addition of bromoacetic acid (10.0 mmol, 8.3 mL of 1.2 M bromoacetic acid stock solution), followed by DIC (10.0 mmol, 1.6 mL, 1.3 g, d = 0.82 g/mL). The reaction mixture was stirred in the microwave reactor at 35 °C (300 W max power, ramp 30 s, hold 1 min, stirring level 2). The resin was then washed using the same washing sequence. Displacement reactions were performed by the addition of primary amine, Nch (3.8 mmol, 1.0 M in NMP, 3.8 ml), Nsch (3.8 mmol, 1.0 M in NMP, 3.8 ml), Npm (5.0 mmol, 1.0 M in NMP, 5.0 mL), Nspe (3.8 mmol, 1.0 M in NMP, 3.8 ml), Ndp (3.8 mmol, 1.0 M in NMP, 3.8 ml), Nlys(Boc) (5.0 mmol, 1.0 M in NMP, 5.0 mL), or Nlys(Mmt) (5.0 mmol, 1.0 M in NMP, 5.0 mL), followed by stirring at 80 °C in the microwave reactor (300 W max power, ramp 2 min, hold 90 s, stirring level 2). The resin was washed using the same washing sequence. Bromoacylation and displacement reactions were repeated until the desired sequence was obtained. After synthesis of the peptoid sequence, the resin-bound peptoid was reacted with 5(6)-carboxyfluorescein (2.5 mmol, 0.94 g), N,N′diisopropyl carbodiimide (2.5 mmol, 0.32 g, 0.40 mL, d = 0.81 g/mL), and 1-



hydroxybenzotriazole hydrate (2.5 mmol, 0.34 g) in DMF (10.0 mL) for 16 h in the reaction vessel on a shaker at room temperature. Reactions were stopped by washing the resins as described above. Subsequently, the peptoids were treated with piperidine/DMF (1:4, v/v) to remove ester-bound carboxyfluorescein.30 After dye conjugation, the methoxytrityl protecting group was removed by multiple treatments with a 0.75% TFA cocktail (CH2Cl2:TFA = 99.25:0.75). The deprotected resin-bound peptoid was treated with DIEA (10.0 mmol, 1.8 mL, 1.3 g, d = 0.74 g/mL) and 1H-pyrazole-1-carboxamidine (10.0 mmol, 1.5 g) in DMF (10.0 mL), and heated at 50 °C for 24–48 h. After guanidinylation, the resin was washed and reacted for 1 h with a cleavage cocktail (TFA:CH2Cl2:TIS = 95:2.5:2.5). General procedure of peptide synthesis: Standard Fmoc/tBu and microwave-assisted solidphase peptide synthesis was used. Fmoc-Rink amide MBHA resin (0.65 mmol/g, 769 mg, 0.50 mmol) was swelled in DMF (10.0 mL) for 20 min, and Fmoc deprotection reaction was carried out following the procedure detailed above. For peptide coupling, Fmoc-Arg(pbf)-OH (0.8 mmol, 0.5 g, 0.08 M in DMF, 10.0 mL), HATU (0.8 mmol, 0.3 g), and DIEA (2.08 mmol, 0.4 mL, 0.3 g, d = 0.74 g/mL) were added, and the reaction mixture was stirred in the microwave reactor (300 W max power, ramp 2 min, hold 8 min, stirring level 2) at 75 °C. The peptide coupling and Fmoc deprotection reactions were repeated until the desired sequence was obtained. The carboxyfluorescein conjugation was performed following the procedure mentioned above. The resin was washed and reacted for 2 h with a cleavage cocktail (TFA:CH2Cl2:TIS = 95:2.5:2.5). Synthesis of peptoid 11-15: After synthesis of the resin-bound peptoid sequence, the resin in DMF (10.0 mL) was added with Boc2O (5.5 mmol, 1.2 g) and DMAP (catalytic amount). The reaction mixture was stirred in the microwave reactor (75 °C, 400 W maximum power, 75%, ramp 8 min, hold 52 min, stirring level 3), and washed with DMF (1×), CH2Cl2 (3×), DMF


Page 16 of 26

Page 17 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(2×), MeOH (2×), DMF (3×), and CH2Cl2 (3×). After the N-terminal Boc protection, Mmt deprotection, guanidylation, and resin cleavage were performed as detailed above. Flow cytometry. HeLa cells were seeded at a density of 350,000 cells in a six-well culture dish (SPL Life Sciences, Seoul, South Korea). After 24 h, cells were treated with each peptoid (5 µM) for 1 h and washed twice with phosphate buffered saline (PBS). The cells were trypsinized at 37 °C for 5 min and culture medium was added to deactivate the trypsin. The detached cells were spun down in a conical tube to remove the media and trypsin. After centrifugation, 600 µL of 2% fetal bovine serum (FBS)/PBS was added to each tube to resuspend the cell pellet. Cellular fluorescence signal was recorded using a SH800 flow cytometer (Sony, Tokyo, Japan) with a fluorescein excitation and emission wavelength of 488 and 530 nm, respectively. Measurements were repeated three times and data were expressed as mean ± SEM. Statistical analyses between groups were performed using Prism 7 software (GraphPad Software Inc., La Jolla, USA) Microscopy. HeLa cells were seeded at a density of 150,000 cells in a 35-mm confocal dish (SPL Life Sciences). After 24 h, the cells were treated with a CF-labeled peptoid (5 µM) for 1 h. After treating cells with 50 nM of MitoTracker red for 15 min, the cells were washed three times with PBS and 1 ml of Opti-MEM was added. The cells were live-imaged using an inverted LSM 700 confocal microscope (Carl Zeiss, Jena, Germany) equipped with an oil immersion objective (63×) in the green and red channels. Fluorescence images were processed using ZEN software (Carl Zeiss), and the Pearson’s correlation coefficients (r) of the images were determined using ImageJ software,40 based on the fluorescence of individual cells using optical slices from 20 to 24 independent Z-stacks, each containing two to six fluorescently labeled cells. JC-1 mitochondrial membrane potential assay. HeLa cells (30000 per well) were seeded (200 µL per well) in a clear-bottomed, black, 96-well plate (BD FALCON) one day prior to



assay. JC-1 (750 µM; Sigma-Aldrich) in dimethylsulfoxide stock solution was dissolved in phenol red-free Opti-MEM medium (GIBCO, Franklin Lakes, NJ, USA) to a final concentration of 7.5 µM JC-1 per well. The medium was removed from the plate and 100 µL per well of JC-1 was added. Plates were incubated for 75 min at 37 °C and washed twice with 100 µL of PBS per well. Subsequently, cells were treated with 25 µL of 10 µM of each compound in Opti-MEM and incubated at 37 °C for another hour. Fluorescence was measured at excitation and emission wavelengths of 530 and 580 nm, respectively (‘red’) and 485 and 530 nm, respectively (‘green’) on a Spectramax M5 fluorescence plate reader (Molecular Devices, Sunnyvale, CA, USA). The ratio of red to green fluorescence was determined and the percentage ∆Ψm from each compound was calculated and normalized using the percentage of the untreated cells as 100%. MTS assay. MRC-5 was purchased from the Korean Cell Link Bank and were grown in DMEM media with 10% FBS at 37 ºC with 5% CO2. The MTS cell-viability assay was carried out to determine the effects of peptoids on MRC-5 cell growth.41 Aliquots (100 µL) of medium containing 1.3×104 MRC-5 cells were distributed into each well of a 96-well plate (Eppendorf). The cells were grown in a humidified atmosphere of 5% CO2 in air at 37 ºC and allowed to attach for 24 h. When the cell density reached approximately 70% confluency, the medium was replaced with serial dilutions of the peptoid stock in medium and incubated for 24 h. Twenty microliters of the CellTiter 96 aqueous non-radioactive cell proliferation assay reagent (Promega, Madison, WI, USA), which contains the tetrazolium compound [3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] was added to each well. The plate was incubated for 4 h at 37 ºC to metabolize. The MTS-formazan products in the viable cells were measured at 490 nm using a microplate reader and percentages of cell viability (%) were measured and compared with untreated cells.


Page 18 of 26

Page 19 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


The percentage of cell viability = A/(Acontrol)×100, where A is the absorbance of the test well and Acontrol is the average absorbance of wells containing cells not treated with peptoids. Mitochondrial oxygen consumption rate (OCR) measurement. U87 cells were purchased from ATCC (Manassas, VA) and were maintained in high glucose DMEM (Thermo Fisher Scientific) medium supplemented with 10% fetal bovine serum (Capricorn Scientific, Ebsdorfergrund, Germany), 2 mM glutamine (Thermo Fisher Scientific), and 100 U/mL of penicillin-streptomycin (Thermo Fisher Scientific) in a 37 °C humidified incubator with 5% CO2. In each well, 40,000 cells were seeded in an XF24 cell plate (Agilent) 24 hours prior to assay. After 24 h, the culture medium was replaced by the assay medium consisting of noncarbonated Seahorse XF Base Medium (Agilent) supplemented with 25 mM glucose, 6 mM glutamine, and 1 mM pyruvate. The cells were equilibrated for 1 h in a non-CO2 37 °C incubator. Subsequently, the assay was performed in accordance with the manufacturer’s instructions (Seahorse XF Cell Mito Stress Test Kit; Agilent). The analysis of OCR was performed in a Seahorse XFe24 analyzer, and the OCR values were obtained during baseline (prior to addition of any Mito Stress Test substances) and after the addition of oligomycin (2 µM final concentration), FCCP (0.5 µM final concentration), and rotenone/antimycin A (0.5 µM final concentration).

ASSOCIATED CONTENT Supporting Information. Confocal images of HeLa cells treated with compounds 1–10 (Figure S2 and S3). Detailed characterization data for compounds 1–15 (Figure S4 and Table S1)

AUTHOR INFORMATION Corresponding authors [email protected]



[email protected] Notes These authors declare no competing financial interest.

ACKNOWLEDGEMENTS This research was financially supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2015R1C1A2A01055457 to J.L.) and by the Ministry of Education (NRF2017R1D1A1B03036089 to J.S.). J.S. also acknowledges a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI16C1074).

ABBREVIATIONS di-tert-butyl dicarbonate (Boc2O); tert-butoxycarbonyl (Boc); 9-fluorenylmethoxycarbonyl (Fmoc); trifluoroacetic acid (TFA); N,N-dimethylformamide (DMF); N,Ndiisopropylcarbodiimide (DIC); triisopropylsilane (TIS); N-methyl-2-pyrrolidone (NMP); N,N-diisopropylethylamine (DIEA); 4-(dimethylamino)pyridine (DMAP); (S)-(-)-αmethylbenzylamine (Nspe); benzylamine (Npm); N-tert-butoxycarbonyl-1,4-butanediamine (Nlys(Boc)); N-methoxytrityl-1,4-butanediamine (Nlys(Mmt)); cyclohexanemethylamine(Nch); (S)-(+)-1-cyclohexylethylamine(Nsch); 2,2diphenylethylamine(Ndp); 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (pbf); 1[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU).

REFERENCES


Page 20 of 26

Page 21 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(1)

Malty, R. H., Jessulat, M., Jin, K., Musso, G., Vlasblom, J., Phanse, S., Zhang, Z., and Babu, M. (2015) Mitochondrial targets for pharmacological intervention in human disease. J. Proteome Res. 14, 5-21.

(2)

Weinberg, S. E., and Chandel, N. S. (2015) Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 11, 9-15.

(3)

Dong, L. F., and Neuzil, J. (2014) Mitochondria in cancer: why mitochondria are a good target for cancer therapy. Prog. Mol. Biol. Transl. Sci. 127, 211-227.

(4)

Fulda, S., Galluzzi, L., and Kroemer, G. (2010) Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447-464.

(5)

Sivitz, W. I., and Yorek, M. A. (2010) Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid. Redox Signal. 12, 537-577.

(6)

Johri, A., and Beal, M. F. (2012) Mitochondrial dysfunction in neurodegenerative diseases. J. Pharmacol. Exp. Ther. 342, 619-630.

(7)

Smith, R. A., Hartley, R. C., and Murphy, M. P. (2011) Mitochondria-targeted small molecule therapeutics and probes. Antioxid. Redox Signal. 15, 3021-3038.

(8)

Murphy, M. P. (2008) Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta 1777, 1028-1031.

(9)

Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G.,

Lopez,

M.,

and

Kalyanaraman,

B.

(2017)

Mitochondria-targeted

triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem. Rev. 117, 10043-10120. (10)

Szeto, H. H. (2006) Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J. 8, E277-283.



(11)

Rocha, M., Hernandez-Mijares, A., Garcia-Malpartida, K., Banuls, C., Bellod, L., and Victor, V. M. (2010) Mitochondria-targeted antioxidant peptides. Curr. Pharm. Des. 16, 3124-3131.

(12)

Szeto, H. H., and Schiller, P. W. (2011) Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development. Pharm. Res. 28, 2669-2679.

(13)

Horton, K. L., Stewart, K. M., Fonseca, S. B., Guo, Q., and Kelley, S. O. (2008) Mitochondria-penetrating peptides. Chem. Biol. 15, 375-382.

(14)

Jean, S. R., Ahmed, M., Lei, E. K., Wisnovsky, S. P., and Kelley, S. O. (2016) Peptide-mediated delivery of chemical probes and therapeutics to mitochondria. Acc. Chem. Res. 49, 1893-1902.

(15)

Lei, E. K., and Kelley, S. O. (2017) Delivery and release of small-molecule probes in mitochondria using traceless linkers. J. Am. Chem. Soc. 139, 9455-9458.

(16)

Buondonno, I., Gazzano, E., Jean, S. R., Audrito, V., Kopecka, J., Fanelli, M., Salaroglio, I. C., Costamagna, C., Roato, I., Mungo, E. et al. (2016) Mitochondriatargeted doxorubicin: a new therapeutic strategy against doxorubicin-resistant osteosarcoma. Mol. Cancer Ther. 15, 2640-2652.

(17)

Zuckermann, R. N., Kerr, J. M., Kent, S. B., and Moos, W. H. (1992) Efficient method for the preparation of peptoids [oligo (N-substituted glycines)] by submonomer solid-phase synthesis. JACS 114, 10646-10647.

(18)

Schroder, T., Niemeier, N., Afonin, S., Ulrich, A. S., Krug, H. F., and Brase, S. (2008) Peptoidic amino- and guanidinium-carrier systems: targeted drug delivery into the cell cytosol or the nucleus. J. Med. Chem. 51, 376-379.

(19)

Kolmel, D. K., Horner, A., Ronicke, F., Nieger, M., Schepers, U., and Bräse, S. (2014) Cell-penetrating peptoids: introduction of novel cationic side chains. Eur. J. Med. Chem. 79, 231-243.


Page 22 of 26

Page 23 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(20)

Jong, T., Perez-Lopez, A. M., Johansson, E. M., Lilienkampf, A., and Bradley, M. (2015) Flow and microwave-assisted synthesis of N-(triethylene glycol)glycine oligomers and their remarkable cellular transporter activities. Bioconjug. Chem. 26, 1759-1765.

(21)

Unciti-Broceta, A., Diezmann, F., Ou-Yang, C. Y., Fara, M. A., and Bradley, M. (2009) Synthesis, penetrability and intracellular targeting of fluorescein-tagged peptoids and peptide-peptoid hybrids. Bioorg. Med. Chem. 17, 959-966.

(22)

Jing, X., Foged, C., Martin-Bertelsen, B., Yaghmur, A., Knapp, K. M., Malmsten, M., Franzyk, H., and Nielsen, H. M. (2016) Delivery of siRNA complexed with palmitoylated

alpha-Peptide/beta-Peptoid

cell-penetrating

peptidomimetics:

membrane interaction and structural characterization of a lipid-based nanocarrier system. Mol. Pharm. 13, 1739-1749. (23)

Huang, W., Seo, J., Lin, J. S., and Barron, A. E. (2012) Peptoid transporters: effects of cationic, amphipathic structure on their cellular uptake. Mol. Biosyst. 8, 2626-2628.

(24)

Vollrath, S. B., Furniss, D., Schepers, U., and Bräse, S. (2013) Amphiphilic peptoid transporters--synthesis and evaluation. Org. Biomol. Chem. 11, 8197-8201.

(25)

Chongsiriwatana, N. P., Patch, J. A., Czyzewski, A. M., Dohm, M. T., Ivankin, A., Gidalevitz, D., Zuckermann, R. N., and Barron, A. E. (2008) Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc. Natl. Acad. Sci. U. S. A. 105, 2794-2799.

(26)

Shin, H. M., Kang, C. M., Yoon, M. H., and Seo, J. (2014) Peptoid helicity modulation: precise control of peptoid secondary structures via position-specific placement of chiral monomers. Chem. Commun. (Camb.) 50, 4465-4468.



(27)

Wu, C. W., Sanborn, T. J., Huang, K., Zuckermann, R. N., and Barron, A. E. (2001) Peptoid oligomers with alpha-chiral, aromatic side chains: sequence requirements for the formation of stable peptoid helices. J. Am. Chem. Soc. 123, 6778-6784.

(28)

Mokranjac, D., and Neupert, W. (2009) Thirty years of protein translocation into mitochondria: unexpectedly complex and still puzzling. Biochim. Biophys. Acta 1793, 33-41.

(29)

Montalbetti, C. A., and Falque, V. (2005) Amide bond formation and peptide coupling. Tetrahedron 61, 10827-10852.

(30)

Fischer, R., Mader, O., Jung, G., and Brock, R. (2003) Extending the applicability of carboxyfluorescein in solid-phase synthesis. Bioconjug. Chem. 14, 653-660.

(31)

Barlow, A. L., Macleod, A., Noppen, S., Sanderson, J., and Guerin, C. J. (2010) Colocalization analysis in fluorescence micrographs: verification of a more accurate calculation of pearson's correlation coefficient. Microsc. Microanal. 16, 710-724.

(32)

Kirshenbaum, K., Barron, A. E., Goldsmith, R. A., Armand, P., Bradley, E. K., Truong, K. T., Dill, K. A., Cohen, F. E., and Zuckermann, R. N. (1998) Sequencespecific polypeptoids: a diverse family of heteropolymers with stable secondary structure. Proc. Natl. Acad. Sci. U. S. A. 95, 4303-4308.

(33)

Wu, C. W., Kirshenbaum, K., Sanborn, T. J., Patch, J. A., Huang, K., Dill, K. A., Zuckermann, R. N., and Barron, A. E. (2003) Structural and spectroscopic studies of peptoid oligomers with alpha-chiral aliphatic side chains. J. Am. Chem. Soc. 125, 13525-13530.

(34)

Roy, O., Dumonteil, G., Faure, S., Jouffret, L., Kriznik, A., and Taillefumier, C. (2017) Homogeneous and robust polyproline type I helices from peptoids with nonaromatic alpha-chiral side chains. J. Am. Chem. Soc. 139, 13533-13540.


Page 24 of 26

Page 25 of 26 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(35)

Perry, S. W., Norman, J. P., Barbieri, J., Brown, E. B., and Gelbard, H. A. (2011) Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques 50, 98-115.

(36)

Reily, C., Mitchell, T., Chacko, B. K., Benavides, G., Murphy, M. P., and DarleyUsmar, V. (2013) Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol. 1, 86-93.

(37)

Bielski, E. R., Zhong, Q., Brown, M., and da Rocha, S. R. (2015) Effect of the conjugation density of triphenylphosphonium cation on the mitochondrial targeting of poly(amidoamine) dendrimers. Mol. Pharm. 12, 3043-3053.

(38)

Trnka, J., Elkalaf, M., and Andel, M. (2015) Lipophilic triphenylphosphonium cations inhibit mitochondrial electron transport chain and induce mitochondrial proton leak. PLoS One 10, e0121837.

(39)

Olivos, H. J., Alluri, P. G., Reddy, M. M., Salony, D., and Kodadek, T. (2002) Microwave-assisted solid-phase synthesis of peptoids. Org. Lett. 4, 4057-4059.

(40)

Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671-675.

(41)

Huang, W., Seo, J., Willingham, S. B., Czyzewski, A. M., Gonzalgo, M. L., Weissman, I. L., and Barron, A. E. (2014) Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity. PLoS One 9, e90397.



Mitochondria-targeting peptoids

Ho Yeon Nam,†, ‡ Jong-Ah Hong,§,‡ Jieun Choi,† Seungheon Shin,± Steve K. Cho,+,± Jiwon Seo,†,* and Jiyoun Lee §,*

†

Department of Chemistry, School of Physics and Chemistry, ±School of Life Sciences, Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea § Department of Global Medical Science, Sungshin University, Seoul 01133, Republic of Korea +

‡

These authors contributed equally to this work.

Table of Contents graphic


Page 26 of 26

Mitochondria-Targeting Peptoids - Bioconjugate Chemistry (ACS

Recommend Documents